| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Pathology Division,* the Cancer Transcriptome Project, and the Center for Medical Genomics,¶ National Cancer Center Research Institute, Tokyo; the Department of Pathology, School of Medicine, Keio University, Tokyo; and the Department of Obstetrics and Gynecology, University of Tokyo, Tokyo, Japan
Of all of the epithelial ovarian cancers, clear cell carcinoma (CCC) of the ovary has the worst prognosis. We applied the oligonucleotide array technique to identify genes generally involved in CCC. Of the 
12,600 genes that were analyzed, 28 were expressed significantly differently between four CCC and seven non-CCC cell lines. Among 16 up-regulated genes in CCC, we further investigated a transcription factor, hepatocyte nuclear factor-1ß (HNF-1ß). We validated up-regulation of HNF-1ß in CCC in terms of both mRNA and protein level using real-time quantitative reverse transcriptase-polymerase chain reaction and immunoblotting. Immunohistochemical analysis of 83 surgically resected ovarian cancers showed that almost all CCC specimens (21 of 22 cases) had nuclear staining for HNF-1ß, whereas most non-CCC specimens (60 of 61 cases) showed no immunostaining or only focal and faint staining in the nucleus. Furthermore, we investigated the significance of HNF-1ß expression in CCC using RNA interference. The reduction of HNF-1ß expression by RNA interference induced apoptotic cell death in ovarian CCC cells, which was confirmed by terminal dUTP nick-end labeling and fluorescence-activated cell-sorting analyses. Our results suggest that HNF-1ß is not only an excellent CCC-specific molecular marker but also a molecular target for therapy of ovarian CCC.
This article has been cited by other articles:
 |
|
 |
|
  D. S P Tan and S. Kaye Ovarian clear cell adenocarcinoma: a continuing enigma J. Clin. Pathol., April 1, 2007; 60(4): 355 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pectasides, E. Pectasides, A. Psyrri, and T. Economopoulos Treatment Issues in Clear Cell Carcinoma of the Ovary: A Different Entity? Oncologist, November 1, 2006; 11(10): 1089 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. DiFeo, G. Narla, J. Hirshfeld, O. Camacho-Vanegas, J. Narla, S. L. Rose, T. Kalir, S. Yao, A. Levine, M. J. Birrer, et al. Roles of KLF6 and KLF6-SV1 in Ovarian Cancer Progression and Intraperitoneal Dissemination. Clin. Cancer Res., June 15, 2006; 12(12): 3730 - 3739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I.-M. Shih and R. J. Kurman Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges Clin. Cancer Res., October 15, 2005; 11(20): 7273 - 7279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Hartmann, K. H. Lu, G. P. Linette, W. A. Cliby, K. R. Kalli, D. Gershenson, R. C. Bast, J. Stec, N. Iartchouk, D. I. Smith, et al. Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy Clin. Cancer Res., March 15, 2005; 11(6): 2149 - 2155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Xu, M. Capezzone, X. Xu, and J. M. Hershman Activation of Nicotinamide N-Methyltransferase Gene Promoter by Hepatocyte Nuclear Factor-1{beta} in Human Papillary Thyroid Cancer Cells Mol. Endocrinol., February 1, 2005; 19(2): 527 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I.-M. Shih and R. J. Kurman Ovarian Tumorigenesis: A Proposed Model Based on Morphological and Molecular Genetic Analysis Am. J. Pathol., May 1, 2004; 164(5): 1511 - 1518. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
